ERBB2 and triple-negative breast carcinoma: In the context of triple-negative breast cancer (TNBC), our results offer a contrasting perspective to Liu et al. (2025), who concluded that having an HER2-low status is associated with improved recurrence-free survival (RFS) in TNBC patients [30].